Search Results - jesus+campagna

6 Results

Sort By:

2021-241: Enhancers of Brain Gamma Oscillations for Treatment of Neurological Disorders

SUMMARY: UCLA researchers in the Department of Neurology have developed a novel small molecule to improve native gamma oscillations as a treatment for cognitive decline in various neurological disorders. BACKGROUND: Neural circuits are facilitated by brain oscillations or rhythmic electric activity at distinct frequencies. These frequency variations...

Published: 9/5/2023 | Inventor(s): Varghese John, Istvan Mody, Jesus Campagna, Barbara Jagodzinska, Xiaofei Wei

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Psychiatry And Mental Health

2020-832: Novel Compounds Targeting APOE4 That Enhance Brain SIRT1 Levels and Target Novel Mechanism of Action

Researchers at UCLA's Drug Discovery Lab and Department of Chemistry have developed new chemical entity (NCE) analogs of A03, which together form a new class of compounds that target apolipoprotein E4 (ApoE4)-mediated deficits in the tau deacetylase enzyme, sirtuin 1 (SirT1). These NCEs provide an opportunity for novel therapeutic development in Alzheimer's...

Published: 9/5/2023 | Inventor(s): Varghese John, Jesus Campagna, Michael Jung

Keywords(s): Brain

Category(s): Therapeutics

2018-200 AMYLOID PRECURSOR PROTEIN-SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER’S DISEASE

Amyloid Precursor Protein-Selective BACE Inhibitors for Alzheimer’s DiseaseSUMMARYUCLA researchers in the Department of Neurology have invented novel Alzheimer’s disease (AD) therapeutics that are selective for BACE1 inhibition and cleavage of the amyloid precursor protein (APP) substrate.BACKGROUNDAlzheimer’s disease is characterized...

Published: 7/19/2023 | Inventor(s): Barbara Jagodzinska, Varghese John, Patricia Spilman, Jesus Campagna

Keywords(s): Cns, Life Science Research Tools, Medical Devices and Materials, Targets And Assays, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Diagnostic Markers > Targets And Assays, Medical Devices, Therapeutics, Therapeutics > CNS and Neurology

2016-305 New 3D-Exoquant Method for the Analysis of Surface Molecules and Quantification of Tissue-Specific Exosomes in Biological Fluids

SUMMARYUCLA researchers in the Department of Neurology have developed a novel high sensitivity exosome and extracellular vesicle disease detection technology for use in the clinical and research setting. BACKGROUNDDetection of surface biomarkers located on extracellular bodies, such as vesicles and exosomes is of great clinical and research significance...

Published: 7/19/2023 | Inventor(s): Varghese John, Patricia Spilman, Jesus Campagna, Peter Heinzelman, Tina Bilousova

Keywords(s): Diagnostic Markers & Platforms, Diagnostic Platform Technologies (E.G. Microfluidics)

Category(s): Diagnostic Markers, Platforms > Diagnostic Platform Technologies

2017-772 ALLOSTERIC BACE INHIBITORS FOR TREATMENT OF ALZHEIMER’S DISEASE

Allosteric BACE Inhibitors For Treatment Of Alzheimer’s DiseaseSUMMARYUCLA researchers from the Department of Neurology have discovered a new class of drug candidates for Alzheimer’s disease. These small molecule compounds can specifically inhibit target enzymes to prevent target protein cleavage through an allosteric mechanism, preventing...

Published: 9/5/2023 | Inventor(s): Varghese John, Barbara Jagodzinska, Patricia Spilman, Jesus Campagna, Kanagasabai Vadivel, Michael Jung

Keywords(s): Cns, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > CNS and Neurology

2014-864 ApoE4-Targeted Therapeutics that Increase SIRT1

ApoE4-Targeted Theraputics That Increase SIRT1SUMMARYUCLA researchers have identified Alaproclate (A03) as a promising drug candidate to treat Mild Cognition Impairment (MCI) and Alzheimer’s disease (AD) through inhibition of the ApoE4 neurotoxicity.BACKGROUNDAlzheimer’s disease (AD) is a neurodegenerative disease whose cause is largely...

Published: 7/19/2023 | Inventor(s): Michael Jung, Varghese John, Dale Bredesen, Barbara Jagodzinska, Jesus Campagna, Ram Rao, Johnny Pham

Keywords(s):

Category(s): Therapeutics, Therapeutics > CNS and Neurology